News & Updates
Filter by Specialty:
Post-COVID sequelae conditions identified, could help establish definition
Patients diagnosed with COVID-19 could have an increased risk of certain conditions up to 120 days post-diagnosis, a finding which could help establish the definition of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC), according to a study presented at CROI 2022.
Post-COVID sequelae conditions identified, could help establish definition
08 Mar 2022Neoplastic progression to pancreatic cancer slips by imaging surveillance
Imaging-based surveillance techniques may miss hallmarks of progression in high-risk individuals presenting with high-grade dysplasia or pancreatic cancer, suggesting a need for more sensitive tools, a recent study has found.
Neoplastic progression to pancreatic cancer slips by imaging surveillance
08 Mar 2022Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
Among advanced hepatocellular carcinoma patients being treated with immune checkpoint inhibitors (ICIs), the occurrence of multisystem and more severe immune-related adverse events is a favourable signal, being associated with survival advantage, according to a Singapore study.
Immune-related adverse events portend better prognosis in ICI-treated hepatocellular carcinoma
08 Mar 2022Severe hypoglycaemia raises risk of heart failure in adults with T2D
Severe hypoglycaemia may contribute to a higher risk of incident heart failure (HF) among adults with type 2 diabetes (T2D), reports a study.
Severe hypoglycaemia raises risk of heart failure in adults with T2D
08 Mar 2022COVID-19 vaccines less effective in immunocompromised people
Immunocompromised patients, particularly those who had undergone organ transplants, show markedly lower seroconversion rates after vaccination against the coronavirus disease 2019 (COVID-19), according to a recent Singapore meta-analysis.
COVID-19 vaccines less effective in immunocompromised people
08 Mar 2022Selective TYK2 inhibitor safe, works against psoriatic arthritis
Deucravacitinib, a selective TYK2 inhibitor, is well tolerated and appears to produce marked improvements in American College of Rheumatology 20 (ACR20) and other endpoints in the treatment of patients with psoriatic arthritis (PsA), according to the results of a phase II study.
Selective TYK2 inhibitor safe, works against psoriatic arthritis
08 Mar 2022Medication risks an acceptable trade-off for cure of IBS symptoms
Patients with irritable bowel syndrome (IBS) are willing to take on significant medication risks in exchange for a permanent cure of their symptoms, a study has found.